Objectives: The objective of this study was to retrospectively evaluate neurologic status pre-and posttreatment with the oral farnesyltransferase inhibitor lonafarnib in children with Hutchinson-Gilford progeria syndrome (HGPS), a rare, fatal disorder of segmental premature aging that results in early death by myocardial infarction or stroke.
Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder of premature aging for which there is no known cure, with an incidence of 1 in 4-8 million live births. 1 HGPS results from a mutation in LMNA, which causes accumulation of an aberrant form of the inner nuclear membrane protein lamin A, called progerin, resulting in cellular dysfunction. 2 Clinically affected children present with severe failure to thrive, accompanied by a phenotype characterized by alopecia, lipoatrophy, joint contractures, skeletal dysplasia, and atherosclerosis with preserved cognitive function. 3 Children die of myocardial infarction or stroke at an average age of 13 years. 4 Farnesyltransferase inhibitors (FTIs) are small molecules that reversibly bind to the farnesyltransferase CAAX binding site, 5 leading to inhibition of progerin farnesylation, which is a crucial posttranslational processing step for protein intercalation into the inner nuclear membrane. In vitro treatment of progerin-containing cells with FTIs normalizes both structure and function. 6 In addition, use of FTIs in the murine transgenic model of HGPS results in improved cardiovascular disease 7 and extended lifespan. 8 In a phase II study of the FTI lonafarnib, primary Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. outcome success was predefined as a 50% increase over pretherapy estimated annual rate of weight gain or change from weight loss to statistically significant on-therapy weight gain. 9 In this study, we retrospectively reviewed neurologic features at baseline and during treatment with the oral FTI lonafarnib.
METHODS We used a retrospective design to analyze neurologic outcomes after treatment with lonafarnib. The open-label study was proposed to provide Class IV evidence for improved neurologic status. Primary outcomes were change in headache, TIA, and stroke frequency. Data. Most pretrial clinical information was obtained from The Progeria Research Foundation Medical and Research Database with parental consent (Brown University Center for Gerontology and Healthcare Research). For some patients, additional pretherapy clinical information was provided directly from the referring physicians. At study entry, participant and parent were administered a semistructured interview that included general health, cardiovascular neurologic symptoms, and stroke history. This was repeated in person at each study visit every 4 months and at completion of the study. All patients underwent serial physical and neurologic examinations at each visit; only patients with known prior seizures, strokes, and/or TIAs were also assessed by a neurologist.
Statistics. Data summaries are primarily descriptive and presented using percentages and 90% exact binomial confidence intervals (CIs). The comparison of headache incidence at study entry and completion is based on the McNemar test.
Standard protocol approvals, registrations, and patient consents. Baseline neurologic status. All patients were assessed for neurologic symptoms and stroke history at baseline (table). Prior neuroimaging was available for review in a subset of patients (n 5 13); at baseline, 8 of 13 patients (62%; 90% CI 35%-83%) had neuroimaging evidence of prior infarction (figure 1). Only 4 patients (15%) reported clinical history of strokes with frequency of 1.75/year in the 12 months before study entry (range 1-3/year). Three of these patients also had a history of TIAs. The remaining 4 patients displaying infarction on imaging were considered to have prior clinically silent strokes. Overall, 4 study patients reported a history of seizures, 3 of whom also had a history of stroke. At trial entry, 15 of 26 patients (58%; 90% CI 40%-74%) were experiencing headaches, with an average frequency of 0.9/ week. Headaches had a migraine quality. Photosensitivity was noted in the majority of patients, with or without headache. Aspirin alone 14 14
Aspirin 1 clopidogrel 1 0
Aspirin 1 clopidogrel 1 acetazolamide 1 0
Aspirin 1 ticlopidine 1 warfarin 1 cilostazol 1 0
Aspirin 1 ticlopidine 1 cilostazol 0 1
Abbreviation: N/A 5 not applicable. a For pretherapy group, this datum refers to the 12 months before treatment. b For all on-therapy data except stroke incidence, total cohort n 5 25 because of death of one patient from stroke at month 5 of therapy. c One stroke occurred in a patient with history of clinical stroke and one occurred in a previously unaffected subject.
Pretrial medications. Seventeen of 26 participants (65%) were taking daily aspirin, with an average daily dose of 5.8 mg/kg. Three patients were taking more than one antiplatelet or anticoagulant agent or acetazolamide (table) . Other relevant medications included cholesterol-lowering agents (n 5 6) and recombinant human growth hormone (n 5 6).
Changes in neurologic status after lonafarnib therapy.
Participants were assessed for recurrent neurologic symptoms at each study visit and at trial completion (table). One child with a history of strokes died of a stroke after 5 months in the study. None of the 3 other patients who had reported clinical strokes at trial entry experienced recurrent TIA or stroke during treatment. One patient with no known history of clinically evident stroke and no prior neuroimaging studies experienced acute hemiparesis accompanied by headache and increased fatigue. CT angiogram demonstrated dense calcification and stenosis of both cervical internal carotid arteries, and subsequent MRI demonstrated a subacute infarction in the left frontal region (figure 2). Stroke was presumed to have been contributed by baseline cerebrovascular disease in the setting of relative dehydration. Nonstudy medications were managed by each patient's own local treating physician. Overall, concomitant use of secondary anticoagulant agents was decreased during the study intervention. Two patients discontinued use of clopidogrel and one patient discontinued use of warfarin because of improved clinical symptoms and lack of new strokes or TIAs, although all 3 children continued daily aspirin therapy. Two patients without prior stroke symptoms discontinued use of aspirin because of minor bleeding.
The number of patients reporting headaches decreased from 15 at study entry to 7 at the time of study completion; there were no new patients reporting headaches during the study (McNemar p value 5 0.005). In addition, there was a concomitant decrease in overall headache frequency to an average of 0.37/week (41% of baseline frequency). No patient experienced recurrent or new onset of seizures during the study period.
DISCUSSION Twenty-five patients with HGPS received the FTI lonafarnib for a minimum of 2 years. Treatment was associated with weight gain success, as well as cardiovascular, skeletal, and audiologic improvements with minimal side effects. 9 Before treatment, more than half of the study participants had a history of headaches, 4 had a history of TIA or strokes, and 4 had a history of seizure. During lonafarnib treatment, the observed frequency of stroke was decreased, which may be of particular relevance to those children with known symptomatic cerebrovascular disease and frequent TIAs at study entry. Only 1 of 4 patients with known history of clinical stroke had a new stroke. Overall, both the prevalence and frequency of headaches were reduced.
Neurologic outcomes were not identified as primary or secondary outcomes in the parent study because the reported prevalence rates of clinical stroke, TIA, and seizure were unknown and presumed too low to utilize as statistically analyzable outcome measures of treatment efficacy. Our pilot data suggest that treatment with lonafarnib may alter the progression of one of the primary morbidities (cerebrovascular disease) in this devastating condition within a relatively short period of time. In addition, because headaches had a high prevalence within the cohort and may represent a presenting symptom for strokes and TIAs in children, the statistically significant decrease in both headache prevalence and frequency over the treatment period is promising.
In a recent natural history study in children with HGPS, radiographic evidence of infarction was found in 60% of patients, of which half were likely clinically silent. 10 In subsequent clinical trials, we are evaluating MRI and magnetic resonance angiography of the neck and circle of Willis at initial trial entry and completion in order to better assess baseline characteristics, effects on the cerebrovasculature, and impact on clinically evident and silent infarcts after treatment interventions.
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